The Frequency of Fibromyalgia and its Relationship With Disease Activity in Female Patients With Behçet’s Disease: A Cross Sectional Study

Koray AYAR1, Burcu METİN ÖKŞMEN2, Lale ALTAN2, Esra KÖSEGİL ÖZTÜRK2

1Department of Internal Medicine, Division of Rheumatology, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
2Department of Physical Therapy and Rehabilitation, Uludağ University Medical Faculty, Bursa, Turkey

ABSTRACT

Objectives: This study aims to determine the incidence of fibromyalgia (FM) in female patients with Behçet’s disease (BD) and to investigate whether disease activity changes in the presence of FM in female patients with BD.

Patients and methods: This cross-sectional study included 72 female patients with BD (mean age 39.7±10.5 years; range, 22 to 74 years) between June 2018 and February 2019. The frequency of FM was evaluated according to the American College of Rheumatology alternative criteria. Active clinical features and BD activity were evaluated with the Behçet's disease activity form (BDCAF).

Results: The prevalence of FM was 29.2% in the BD patients. BD clinical activity index, patients’ perceptions of disease activity and clinicians’ overall perceptions of disease activity scores were significantly higher in BD patients with FM (p=0.003, p<0.001 and p=0.025, respectively). The active clinical features of BD were not different between the groups except for genital ulcer. The prevalence of active genital ulcers was higher in BD patients with FM than in BD patients without FM (38.1% vs. 13.7%, respectively).

Conclusion: Disease activity is higher in female BD patients with FM than those without FM. High disease activity in female BD patients with FM may be associated with the presence of genital ulcers.

Keywords: Behçet's disease, fibromyalgia, genital ulcer.

Fibromyalgia (FM) is a common cause of chronic widespread musculoskeletal pain, often accompanied by fatigue, cognitive disturbance, psychiatric symptoms and multiple somatic symptoms. The prevalence of FM varies between 1.7% and 6.4% in the community and the frequency is increased among patients with chronic inflammatory arthritis and systemic autoimmune rheumatic disease.1-7 In recent years, extensive research has been conducted on the immunological background of FM. In general, the findings do not support the belief that FM is a non-inflammatory rheumatic disease.8-12 In addition, disease activity was found to be higher in rheumatic diseases such as rheumatoid arthritis (RA), axial spondyloarthropathy and Sjögren’s syndrome (SS) accompanied by FM.13-15 Behçet’s disease (BD) is characterized by recurrent oral aphthae and any of the several systemic manifestations including genital aphthae, ocular disease, skin lesions, gastrointestinal involvement, neurologic disease, vascular disease or arthritis. The incidence of FM in BD is higher than in the...
normal population and its frequency ranges from 5.7% to 37.1% according to data from a limited number of studies.\textsuperscript{16} The results of studies investigating the relationship between FM and BD activity are contradictory.\textsuperscript{17-20} BD is known to be more severe in males and FM is more common in females.\textsuperscript{3,21} Therefore, it is not appropriate to evaluate the relationship between disease activity and FM in patients with BD without grouping by sex. In 2013, alternative criteria for classifying FM were developed by the American College of Rheumatology (ACR) and these criteria were easier to use and found to be high in specificity compared to the 2010 ACR preliminary diagnostic criteria for FM.\textsuperscript{22} In this study, we aimed to determine the incidence of FM in female patients with BD and to investigate whether disease activity changes in the presence of FM in female patients with BD.

**PATIENTS AND METHODS**

This cross-sectional study was conducted at Bursa Yüksek İhtisas Training and Research Hospital between June 2018 and February 2019. Among 155 female patients diagnosed with BD in the rheumatology outpatient clinic records, 97 patients who volunteered to participate in the study were included in the first evaluation (ClinicalTrials.gov ID: NCT03543709). Finally, 72 female BD patients (mean age 39.7±10.5 years; range, 22 to 74 years) were included according to the inclusion criteria which were being between the ages of 18 and 75 years and meeting the International Study Group classification criteria.\textsuperscript{23} The exclusion criteria were not cooperating sufficiently to complete the surveys or having thyroid disease, pregnancy, diabetes, chronic renal failure, cancer or systemic rheumatic disease. The participants who were not included in the study as a result of the initial evaluation are summarized in Figure 1 together with the reasons for exclusion. The study protocol was approved by the Uludağ University School of Medicine Clinical Research Ethics Committee (2018-02/14). A written informed consent was obtained from each patient. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Patients’ clinical features, demographic characteristics and medications were recorded. Human leukocyte antigen (HLA)-B51 genetic test results were obtained from patient charts. Behçet’s disease activity form (BDCF) was used by the clinician to assess disease activity.\textsuperscript{24} In BDCF, the presence of 12 clinical features of BD within the last four weeks were questioned. These features consisted of arthralgia, arthritis, diarrhea, erythema nodosum, eye inflammation, genital ulcers, headaches, mouth ulcers, nausea/vomiting, new central nervous system involvement, new major vessel inflammation and pustules. The presence of each clinical feature was scored as 1 point. Behçet’s disease clinical activity index (BDCAI) values of the patients were calculated as a result of the evaluation of these 12 clinical features. In addition, since the symptom of arthralgia would be common in patients with FM and could lead to misinterpretation of the results, the BDCAI values were also calculated on 11 clinical findings without considering the arthralgia symptom and compared between the groups. The patients’ and clinicians’ perceptions of disease activity were evaluated separately with two questions. A Likert scale represented by a ‘smiley face’ was used in these questions. In this scale, clinicians’ and patients’ perceptions of disease activity in the last four weeks were graded with seven different facial expressions ranging from very good to bad. According to these perceptions, patients’ perception of disease activity (PPDA) and clinician’s overall perception of disease activity (CPDA) were scored between 1-7 points.

The ACR alternative criteria were used to classify FM.\textsuperscript{22} Alternative criteria were derived from Symptom Impact Questionnaire (SIQR) symptoms and the 28-area pain location inventory (PLI). In SIQR symptoms, each of the intensities of the common 10 symptoms of FM over the last seven days was graded over 10 points by the patients. The SIQR symptoms score was obtained as half of the total score obtained from the SIQR. In PLI, the patients were asked about 28 specific locations in the body in which they defined persistent pain in the last seven days. The total number of painful locations is the pain location score of the patient. A patient fulfilling the following was defined as having FM: SIQR symptom score ≥21, pain location score ≥17.
Fibromyalgia in Behçet’s disease

Fibromyalgia in Behçet’s disease and symptoms and pain locations persistent for at least three months. Patients were grouped according to the presence of FM, and the activity of BD was compared between the groups.

**Statistical analysis**

The SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used to statistically analyze all data. Kolmogorov-Smirnov test was used to determine whether the data were in normal distribution. To compare quantitative variables, Student’s t-test was used for normally distributed variables, and Mann-Whitney U test was used for variables that were not normally distributed. For the comparison of qualitative data, $\chi^2$ test or Fischer’s exact $\chi^2$ test was used. All tests were two-tailed, and p values <0.05 were considered to indicate statistical significance.

**RESULTS**

Mean age, median disease duration, HLA-B51 genetic test results and clinical features of the patients are given in Table 1. Frequency of FM and PLI and SIQR scores of the patients are given in Table 2. The median disease duration of patients with or without FM was 14.0 months (range, 0-360 months) and 36.0 months (range, 0-480 months), respectively. The median disease duration was not different between groups (p=0.081). Active clinical features and BDCAI, BDCAI (without arthralgia), PPDA

| Table 1. Age, disease duration, human leukocyte antigen-B51 genetic test results and clinical features of female patients with Behçet’s disease |
|---------------------------------|
| **Female patients with BD (n=72)** |
| n   | %   | Mean±SD | Median | Min-Max |
|---------------------------------|
| Age (year)                      | 39.7±10.5 |
| Disease duration (month)        | 24.0     | 0-480   |
| HLA-B51                         |          |
| +                               | 48       |
| -                               | 18       |
| Oral ulcerations                | 72       | 100     |
| Genital ulcerations             | 43       | 59.7    |
| Erythema nodosum                | 46       | 63.9    |
| Acneiform lesions               | 56       | 77.8    |
| Eye lesions                     | 14       | 19.4    |
| Venous disease                  | 6        | 8.3     |
| Neurologic disease (parenchymal) | 2       | 2.8     |
| Pathergy                        | 48       | 66.7    |

BD: Behçet’s disease; SD: Standard deviation; HLA-B51: Human leukocyte antigen.

| Table 2. Frequency of fibromyalgia and 28-area pain location inventory and Symptom Impact Questionnaire scores in female patients with Behçet’s disease |
|---------------------------------|
| **Female patients with BD (n=72)** |
| n   | %   | Mean±SD |
|---------------------------------|
| 28-area pain location inventory score | 11.7±7.7 |
| SIQR symptoms score              | 22.5±10.3 |
| 28-area pain location inventory score ≥17 | 23 | 31.9 |
| Symptom Impact Questionnaire score ≥21 | 41 | 56.9 |
| Frequency of fibromyalgia         | 21 | 29.2 |

BD: Behçet’s disease; SD: Standard deviation.
**Table 3.** Active clinical features and Behçet’s disease clinical activity index, patient’s perception of disease activity and clinician’s overall perception of disease activity scores of patients according to data obtained from Behçet’s disease activity form, and medications of patients with or without fibromyalgia

|                                      | Female patients with BD without FM (n=51) | Female patients with BD with FM (n=21) | p       |
|--------------------------------------|------------------------------------------|---------------------------------------|---------|
|                                      | n % Mean±SD Median Min-Max               | n % Mean±SD Median Min-Max             |         |
| Age (year)                           | 40.0±10.4                                | 39.0±10.8                             | 0.692   |
| BDCAF sections                       |                                          |                                       |         |
| Headache                             | 36 70.6 18 85.7                         |                                       | 0.178   |
| Mouth ulceration                     | 35 68.6 17 81.0                         |                                       | 0.289   |
| Genital ulceration                   | 7 13.7 8 38.1                           |                                       | 0.021   |
| Erythema                             | 14 27.5 10 47.6                         |                                       | 0.099   |
| Skin pustules                        | 18 35.3 11 52.4                         |                                       | 0.179   |
| Joints-arthralgia                    | 39 76.5 20 95.2                         |                                       | 0.060   |
| Joints-arthritis                     | 6 11.8 2 9.5                            |                                       | 0.783   |
| Nausea/vomiting/abdominal pain       | 7 13.7 6 28.6                           |                                       | 0.137   |
| Diarrhea + altered/frank blood per rectum | - -                                   |                                       |         |
| Eye involvement                      | 3 5.9 0 0                               |                                       | 0.256   |
| Nervous system involvement           | 1 2.0 1 4.8                            |                                       | 0.511   |
| Major vessel involvement             | 1 2.0 1 4.8                            |                                       | 0.511   |
| Scores of disease activity           |                                          |                                       |         |
| BDCAI                                | 3.0 0-8                                 | 5.0 1-6                               | 0.003   |
| BDCAI (without arthralgia)           | 2.0 0-7                                 | 4.0 0-6                               | 0.004   |
| PPDA                                 | 3.0 1-5                                 | 5.0 17                                | <0.001  |
| CPDA                                 | 2.0 1-4                                 | 3.0 1-5                               | 0.025   |
| Drugs                                |                                          |                                       |         |
| Colchicine                           | 33 64.7 11 52.4                         |                                       | 0.330   |
| Azathioprine                         | 4 7.8 0 0                              |                                       | 0.187   |
| Infliximab                           | 1 2.0 0 0                             |                                       | 0.518   |
| Corticosteroid                       | 6 11.8 5 23.8                         |                                       | 0.197   |
| Duloxetine                           | 2 3.9 2 9.5                           |                                       | 0.575   |

BD: Behçet’s disease; FM: Fibromyalgia; SD: Standard deviation; Min: Minimum; Max: Maximum; BDCAF: Behçet’s disease activity form; BDCAI: Behçet’s disease clinical activity index; CPDA: Clinician’s overall perception of disease activity; PPDA: Patient’s perception of disease activity.
and CPDA scores according to data obtained from BDCAF, and medications of patients with or without FM are shown in Table 3. Active genital ulceration was significantly more frequent in the FM group (p=0.021). All other active clinical features were not significantly different between the groups. The use of corticosteroids, colchicine, azathioprine, infliximab and duloxetine was not different between the groups. Four patients had been using duloxetine treatment for the diagnosis of FM, but two of them did not meet the 2013 ACR classification criteria. The BDCAI, BDCAI (without arthralgia), PPDA and CPDA scores were significantly higher in the FM group (p=0.003, p=0.004, p<0.001 and p=0.025, respectively).

**DISCUSSION**

In this study, we have found that the frequency of FM was 29.2% in female patients with BD and the activity of BD was higher in patients with FM. To the best of our knowledge, this study is the first to show that FM is associated with disease activity in female patients with BD. In rheumatic diseases such as SS, systemic lupus erythematosus, RA and ankylosing spondylitis, FM can be seen more frequently.15,20,25,26 Although the frequency of FM has been adequately investigated in other rheumatic diseases, there are a limited number of studies evaluating the prevalence of FM in BD and the data obtained from these studies showed that the prevalence of FM is increased in patients with BD.16 The first study in which the prevalence of FM was evaluated in BD was conducted by Yavuz et al.,27 and the prevalence of FM was found to be 9.2% among all patients with BD and 90% of the patients with FM were females. In a study conducted by Al-Izzi and Jabber,28 the prevalence of FM was found to be 8.2% in patients with BD and a high rate of female dominance (female/male: 7/1) was observed in BD patients with FM. There is little information about the prevalence of FM in females with BD in the literature. FM was found in 22 (55.0%) of 40 female patients with BD and 12 (21.4%) of 56 female patients with BD, respectively, in the studies of Melikoglu and Melikoglu17 and Lee et al.18 In this study, the frequency of FM was found to be 29.2% among 72 females with BD and the frequency of FM in this study was close to the frequency of FM in BD conducted in Turkey by Melikoglu and Melikoglu.17 To the best of our knowledge, this study includes data from the largest population of female patients with BD in which FM has been investigated.

In many rheumatic diseases, FM is associated with disease activation.13,14 However, the results...
of studies evaluating the relationship between FM and disease activity in Behçet’s patients are conflicting.\textsuperscript{17-20} Melikoglu and Melikoglu\textsuperscript{17} and Lee et al.\textsuperscript{18} have found no association between FM and disease activity in Behçet’s patients. However, in the study of Haliloglu et al.,\textsuperscript{19} the frequency of FM in other rheumatic diseases and its relationship with disease activity were evaluated and disease activity was found to be higher in Behçet’s patients with FM than in non-FM patients. In addition, in the study of El-Rabbat et al.,\textsuperscript{20} BDCAF score was correlated with the widespread pain index. It may not be accurate to evaluate the relationship between disease activity and FM in patients with BD without sex discrimination since FM is common in females while BD is more active in males.\textsuperscript{3,21} In this study, we found that BD activity was significantly higher in patients with FM than patients without FM. Since FM patients will suffer from arthralgia, we also calculated BDCAI and compared it between the groups ignoring the arthralgia, which is one of the parameters used to evaluate the activity of BD. The disease activity of BD was significantly higher in the FM group, even if the symptoms of arthralgia were not considered. In addition, both the clinicians’ and the patients’ perceptions of disease activity were significantly higher in BD patients who also had FM. As a result of studies conducted in the last 10 years, the opinion that FM is not an inflammatory disease has changed to the opinion that FM may have some relationship with inflammation.\textsuperscript{8-12} In some studies, interleukin (IL)-6 and IL-8 levels were found to be high in FM compared to healthy controls and there are many studies showing that these cytokines are also increased in BD.\textsuperscript{29-31} In addition, a study with a small sample size has demonstrated that patients with FM showed a reduction in T-helper-2 (Th2) cytokines, such as IL-4, IL-5 and IL-13.\textsuperscript{32} In the literature, there are also data showing the increase of Th2 cytokines in BD.\textsuperscript{33,34} We know from the data to date that FM is common in BD and according to the data obtained from this study, disease activation is higher in the presence of FM in female patients with BD. Perhaps the presence of FM contributes to inflammation, leading to increased disease activity in BD. Further data on this subject are needed to clarify whether FM contributes to inflammation in BD.

When we evaluated the active clinical features of female BD patients with or without FM, active clinical features were not different between the groups except for genital ulcer. The frequency of active genital ulcers was 38.1% in patients with FM and 13.7% in patients without FM, and the difference between the groups was significant (p=0.021). To our knowledge, no information has been reported on this subject in the literature. Genital ulcer may cause sleep disorder in patients with BD.\textsuperscript{35,36} Sleep disorder is one of the well-known clinical features of FM.\textsuperscript{37} Therefore, one of the factors contributing to the high prevalence of FM in patients with BD may be the presence of genital ulcer through sleep disturbance. Further studies are needed to clarify this issue.

This study has some limitations. Firstly, it was performed with a limited number of patients and the results should to be confirmed by further studies with larger sample size. Moreover, considering that sex affects the activity of BD and the frequency of FM in Behçet’s patients differently, and that there may be different pathogenetic processes according to sex, we conducted our study only on female patients. Thus, we do not know if the same results would be obtained in male patients with BD, which was a limitation. Furthermore, in this study, the activity of BD was measured using BDCAF and the fact that we did not measure other markers of inflammation to assess disease activity was another limitation. Also, the lack of assessment of body mass index and smoking, which may affect inflammation, when comparing disease activation in Behçet’s patients with or without FM was another limitation.

In conclusion, in this study, we have found that BD activity and perceptions of BD activity of both patients and clinicians were higher in female BD patients with FM than those without FM. The presence of FM in patients with BD may be associated with the presence of active genital ulcers. Further studies are required to clarify this situation in which the presence of active genital ulcer is evaluated together with other clinical conditions, such as sleep disorder, which may contribute to FM.

**Declaration of conflicting interests**

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
**Funding**

The authors received no financial support for the research and/or authorship of this article.

**REFERENCES**

1. Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) 2013;65:786-92.

2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.

3. Jones GT, Atzeni F, Beasley M, Flüß E, Sarzi-Puttini P, Macfarlane GJ. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol 2015;67:568-75.

4. Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS One 2015;10:e0138024.

5. Wolfe F, Häuser W, Hassett AL, Katz RS, Walitt BT. The development of fibromyalgia--I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 2011;152:291-9.

6. Lee YC, Lu B, Boire G, Haraoui BP, Hitchon CA, Pope JE, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013;72:949-54.

7. Karaaslan Y, Oztürk M, Haznedaroğlu S. Secondary fibromyalgia in Turkish patients with rheumatologic disorders. Lupus 1999;8:486.

8. Kadetoff D, Lampá J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012;242:33-8.

9. Kosek E, Altawil R, Kadetoff D, Finn A, Westman M, Le Maître E, et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1β in rheumatoid arthritis. J Neuroimmunol 2015;280:49-55.

10. Mendieta D, de la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol 2016;290:22-5.

11. Bote ME, García JJ, Hinchado MD, Ortega E. Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 2012;19:343-51.

12. Imamura M, Targo RA, Hsing WT, Imamura S, Azevedo RS, Boas LS, et al. Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia. Clin Interv Aging 2014;9:939-44.

13. Provan SA, Austad C, Halsaa V, Hammer HB, Kvien TK, Uhlig T. Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. Clin Exp Rheumatol 2019;37:58-62.

14. Macfarlane GJ, Barnish MS, Pathan E, Martin KR, Haywood KL, Siebert S, et al. Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register. Arthritis Rheumatol 2017;69:2144-50.

15. Torrente-Segarra V, Corominas H, Sánchez-Piedra C, Fernández-Castro M, Andreu JL, Martínez-Taboada VM, et al. Fibromyalgia prevalence and associated factors in primary Sjögren’s syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSE). Clin Exp Rheumatol 2017;35 Suppl 105:28-34.

16. Jobanputra C, Richey RH, Nair J, Moots RJ, Goebel A. Fibromyalgia in Behçet’s disease: a narrative review. Br J Pain 2017;11:97-101.

17. Melikoglu M, Melikoglu MA. The prevalence of fibromyalgia in patients with Behçet’s disease and its relation with disease activity. Rheumatol Int 2013;33:1219-22.

18. Lee SS, Yoon HJ, Chang HK, Park KS. Fibromyalgia in Behçet’s disease is associated with anxiety and depression, and not with disease activity. Clin Exp Rheumatol 2005;23(4 Suppl 38):S15-9.

19. Haliloglu S, Carioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int 2014;34:1275-80.

20. El-Rabbat M S, Mahmoud NK, Gheita TA. Clinical significance of fibromyalgia syndrome in different rheumatic diseases: Relation to disease activity and quality of life. Reumatol Clin 2018;14:285-9.

21. Yazıcı H, Tüzün Y, Pazarlı H, Yurdakul S, Ozyazgan Y, Özdoğan H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis 1984;43:783-9.

22. Bennett RM, Friend R, Marcus D, Bernstein C, Han BK, Yachoui R, et al. Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary American College of Rheumatology criteria and the development of alternative criteria. Arthritis Care Res (Hoboken) 2014;66:1364-73.

23. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990;335:1078-80.
24. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet’s disease activity index. Rheumatology (Oxford) 2004;43:73-8.

25. Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O. Fibromyalgia in women with ankylosing spondylitis. Rheumatol Int 2007;27:865-8.

26. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. J Rheumatol 2004;31:695-700.

27. Yavuz S, Fresko I, Hamuryudan V, Yurdakul S, Yazici H. Fibromyalgia in Behçet’s syndrome. J Rheumatol 1998;25:2219-20.

28. Al-Izzi MK, Jabber AS. Fibromyalgia in Iraqi patients with Behcet’s disease. J Med Liban 2004;52:86-90.

29. Uçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011;12:245.

30. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002;31:205-10.

31. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum 2004;50:2291-5.

32. Sturgill J, McGee E, Menzies V. Unique cytokine signature in the plasma of patients with fibromyalgia. J Immunol Res 2014;2014:938576.

33. Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behçet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998;25:329-33.

34. Mantaş C, Direskeneli H, Ekşioglu-Demiralp E, Akoglu T. Serum levels of Th2 cytokines IL-4 and IL-10 in Behçet’s disease. J Rheumatol. 1999;26:510-2.

35. Yazmalar L, Batmaz İ, Sarıyıldız MA, Yıldız M, Uçmak D, Türkçı F, et al. Sleep quality in patients with Behçet’s disease. Int J Rheum Dis. 2017;20:2062-9.

36. Lee J, Kim SS, Jeong HJ, Son CN, Kim JM, Cho YW, et al. Association of sleep quality in Behcet disease with disease activity, depression, and quality of life in Korean population. Korean J Intern Med 2017;32:352-9.

37. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55.